Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 6/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8576816 | 0.90 | GRM5 (0.46) | MAP2K4GRM5ADORA1ADORA2AMEN1 | |
| SCHEMBL90927 | 0.89 | MAP2K4 (0.43) | MAP2K4MAP2K7GRM5ADORA1ADORA2A | |
| SCHEMBL91039 | 0.85 | MAP2K4 (0.43) | MAP2K4MAP2K7MAPK11MAPK14KCNH2 | |
| SCHEMBL90979 | 0.78 | USP30 (0.41) | MAP2K4MAP2K7MAPK11MAPK14KCNH2 | |
| SCHEMBL91035 | 0.77 | USP30 (0.43) | MAP2K4ADORA2A | |
| SCHEMBL8575311 | 0.76 | GRM5 (0.47) | GRM5ADORA1ADORA2AMEN1KMT2A | |
| SCHEMBL91007 | 0.76 | MAP2K4 (0.44) | MAP2K4MAP2K7GRM5ADORA1ADORA2A | |
| SCHEMBL91043 | 0.76 | GRM5 (0.46) | KCNH2GRM5ADORA1ADORA2AMEN1 | |
| SCHEMBL90984 | 0.75 | MAP2K4 (0.43) | MAP2K4MAP2K7GRM5ADORA1 | |
| SCHEMBL90950 | 0.75 | DRD2 (0.50) | MAP2K4MAP2K7MAPK11MAPK14KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MAP2K4 419/4885MAP2K7 391/4885MAPK11 1088/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MAP2K4 419/4885MAP2K7 391/4885MAPK11 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.